Bank of New York Mellon
AQST icon

Bank of New York Mellon’s Aquestive Therapeutics AQST Stock Holding History

Bank of New York Mellon’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
275,544
+20,360
+8% +$85.7K ﹤0.01% 3282
2026
Q1 		$1.06M Sell
255,184
-14,636
-5% -$59.4K ﹤0.01% 3172
2025
Q4 		$1.74M Buy
269,820
+62,581
+30% +$390K ﹤0.01% 2916
2025
Q3 		$1.16M Buy
207,239
+22,323
+12% +$96.5K ﹤0.01% 3127
2025
Q2 		$612K Buy
184,916
+16,028
+9% +$46K ﹤0.01% 3400
2025
Q1 		$490K Sell
168,888
-2,793
-2% -$8.46K ﹤0.01% 3452
2024
Q4 		$611K Sell
171,681
-6,014
-3% -$27.7K ﹤0.01% 3417
2024
Q3 		$885K Sell
177,695
-50,656
-22% -$197K ﹤0.01% 3208
2024
Q2 		$594K Buy
+228,351
New +$763K ﹤0.01% 3484
2024
Q1 		– Sell
-14,853
Closed -$30K – 4162
2023
Q4 		$30K Hold
14,853
– – ﹤0.01% 4198
2023
Q3 		$22.7K Hold
14,853
– – ﹤0.01% 4246
2023
Q2 		$24.5K Hold
14,853
– – ﹤0.01% 4269
2023
Q1 		$16.9K Hold
14,853
– – ﹤0.01% 4325
2022
Q4 		$13.4K Hold
14,853
– – ﹤0.01% 4394
2022
Q3 		$17K Hold
14,853
– – ﹤0.01% 4466
2022
Q2 		$10K Sell
14,853
-99,770
-87% -$133K ﹤0.01% 4546
2022
Q1 		$299K Hold
114,623
– – ﹤0.01% 4024
2021
Q4 		$446K Sell
114,623
-420
-0.4% -$2.11K ﹤0.01% 3876
2021
Q3 		$502K Sell
115,043
-680
-0.6% -$2.67K ﹤0.01% 3804
2021
Q2 		$459K Sell
115,723
-48,536
-30% -$194K ﹤0.01% 3805
2021
Q1 		$854K Buy
164,259
+74,240
+82% +$395K ﹤0.01% 3421
2020
Q4 		$482K Buy
90,019
+39,093
+77% +$234K ﹤0.01% 3631
2020
Q3 		$247K Sell
50,926
-8,342
-14% -$54.5K ﹤0.01% 3777
2020
Q2 		$288K Buy
+59,268
New +$273K ﹤0.01% 3702
2019
Q2 		– Sell
-26,849
Closed -$186K – 4209
2019
Q1 		$186K Buy
26,849
+9,725
+57% +$68.1K ﹤0.01% 3902
2018
Q4 		$108K Buy
+17,124
New +$216K ﹤0.01% 3945

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
EAM
Everstar Asset Management Mooresville, North Carolina $207M AUM 18.14% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Bank of New York Mellon's AQST Position: Q2 2026 in Review

Bank of New York Mellon increased its Aquestive Therapeutics (AQST) stake by 8% in Q2 2026, buying an estimated $85.7K and bringing the position to 275,544 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3282.

Bank of New York Mellon first reported a position in AQST in Q4 2018 and has held it in 26 quarters since. The position peaked at $1.74M in Q4 2025. 86 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Bank of New York Mellon held 275,544 shares of Aquestive Therapeutics worth $1.15M as of Q2 2026.
  • Bank of New York Mellon bought 20,360 Aquestive Therapeutics shares in Q2 2026, an estimated $85.7K.
  • Aquestive Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3282 holding.
  • Bank of New York Mellon first reported a position in Aquestive Therapeutics in Q4 2018 and has held it in 26 quarters since.
  • Bank of New York Mellon's Aquestive Therapeutics position peaked at $1.74M in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.